Stochastic cellular processes, such as gene expression[@R1],[@R2], can cause phenotypic variation even in the absence of genetic variation and within equivalent environments[@R3]--[@R6]. aRME represents an important facet of cellular stochasticity[@R7]--[@R9], although its levels and nature have remained contentious. Early microarray studies reported clonally inherited aRME for 5--15% of genes in bulk-population analyses of long-term cultured human[@R10] and mouse[@R11] cells. These data were the basis for several subsequent investigations of histone modifications over promoters and gene bodies of reported clonal aRME genes[@R12], computational inference of clonal aRME in other cell types[@R12], and an exploration of the phenotypic consequences of clonal aRME[@R8]. Recently, a study analyzed evolutionary signatures in 4,227 inferred clonal aRME genes[@R13], assuming clonal aRME for nearly 20% of autosomal genes. On the other hand, RNA-seq analyses of clonal somatic cell populations arrived at lower rates (2--3%) of clonal aRME[@R14],[@R15], and single-cell studies suggested that high levels of cellular aRME reflect burst-like transcription from each allele[@R16]--[@R18]. However, available single-cell data on allelic expression[@R16]--[@R18] lacked information on clonality, precluding dissection of clonal and dynamic aRME. Finally, transcriptome-wide studies of clonal aRME *in vivo* are completely lacking. Therefore, we used single-cell RNA-seq on clonal primary cells to simultaneously investigate clonal and dynamic aRME. Moreover, by analyzing clonal T-cells isolated directly from human blood, we provide the first global analysis of aRME *in vivo*.

We started by sequencing the transcriptomes of individual mouse primary fibroblasts (n=285, passage 2--4, CAST/EiJxC57BL/6J reciprocal cross, [Supplementary Table 1a](#SD1){ref-type="supplementary-material"}), either picked randomly or after monoclonal expansions, using Smart-seq2[@R19] ([Fig. 1a](#F1){ref-type="fig"}). Seven clones were harvested after 2--7 cellular divisions (4--115 cells). We detected (RPKM\>1) on average 10,702 genes in fibroblasts ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}), exhibiting highly correlating expression levels (average Spearman rho=0.85) ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}) and strain-specific single nucleotide polymorphisms (SNPs) in 82% of genes. Using SNPs, we classified the expression of each gene as biallelic, maternal monoallelic, paternal monoallelic, or not detected, in each cell ([Online Methods](#S2){ref-type="sec"} and [Supplementary Figs. 3--7](#SD1){ref-type="supplementary-material"}).

We first characterized aRME using an expression threshold suitable for determining rates of dynamic aRME (RPKM\>20; see [Online methods](#S2){ref-type="sec"}), and observed 13% (median) monoallelic expression of autosomal genes in fibroblasts ([Fig. 1b](#F1){ref-type="fig"}). To determine the contribution of clonal and dynamic aRME, we investigated whether the monoallelic expression was the same across clonal cells by pooling cellular allelic calls *in silico* and determining the percent consistent monoallelic expression over clonal cells ([Fig. 1c](#F1){ref-type="fig"} and [Supplementary Fig. 6e](#SD1){ref-type="supplementary-material"}). We excluded imprinted genes as well as regions with cell- or clone-specific chromosomal aberrations ([Online Methods](#S2){ref-type="sec"} and [Supplementary Fig. 7](#SD1){ref-type="supplementary-material"}) -- which often appear in cultured cells[@R20]. Since dynamic aRME can generate consistent allelic expression patterns in groups of cells by random chance (with probability inversely related to the number of cells), we contrasted the percent allele-consistent aRME in clones with the levels expected by dynamic aRME alone, by *in silico* pooling of the same number of non-clonal cells ([Fig. 1c](#F1){ref-type="fig"}). This strategy was experimentally validated by physical pooling and joint sequencing of multiple cells from one clone ([Fig. 1d](#F1){ref-type="fig"}). Our data showed that dynamic aRME accounted for nearly all aRME in fibroblasts. Indeed, above the expression-level threshold RPKM\>20 we did not detect clonal aRME (*P*=0.8, one-sided Wilcoxon test), whereas analyses including all expressed genes (RPKM\>1) revealed a low frequency of clonal aRME ([Fig. 1e](#F1){ref-type="fig"}), affecting 0.5% of expressed genes (median, *P*=0.015, one-sided Wilcoxon test). As expected due to X-chromosome inactivation (XCI), X-linked genes had clone-consistent monoallelic expression of a single parental X-chromosome in female cells ([Fig. 1c](#F1){ref-type="fig"} and [Supplementary Fig. 7a--c](#SD1){ref-type="supplementary-material"}) **--** thereby serving as an internal positive control for detectability of clonal monoallelic expression; confirming that the scarcity of clonal aRME was not due to insufficient power. Additionally, the X-chromosome data provided the opportunity to explore properties of genes that escape XCI from a single-cell perspective ([Supplementary Note 1, Supplementary Figs. 8--9 and Supplementary Table 2](#SD1){ref-type="supplementary-material"}).

Thus, our data demonstrate that dynamic aRME constitutes the vast majority (\>95%) of aRME occurring in primary fibroblasts. Next, to identify individual clonal aRME genes we devised a gene-level test detecting significantly skewed frequencies of monoallelic expression compared to the background expectation of random allelic expression fluctuation ([Online Methods](#S2){ref-type="sec"} and [Supplementary Fig. 6f](#SD1){ref-type="supplementary-material"}). Genetic biases in allelic expression were observed for \~24% of genes ([Supplementary Fig. 10](#SD1){ref-type="supplementary-material"}), in line with a recent study[@R21], and were accounted for in the background expectation. We validated our gene-level test on imprinted genes (i.e. parental-specific monoallelic expression), which were reliably identified ([Fig. 2a--b](#F2){ref-type="fig"} and [Supplementary Table 3a](#SD1){ref-type="supplementary-material"}). As further validation of sensitivity in allele-specific detection using our single-cell assay, we performed deep sequencing on bulk RNA extracted from a fibroblasts culture using stranded mRNA TruSeq, and found that the single-cell data performed at least equally well in correctly identifying known imprinted genes ([Supplementary Note 2, Supplementary Table 3b and Supplementary Fig. 9b](#SD1){ref-type="supplementary-material"}; including information on allelic expression leakage of the imprinted gene *Impact*). Next, we applied the gene-level test on the two largest fibroblast clones (having adequate number of cells) and found significant (FDR\<5%) clonal aRME for 41 and 47 autosomal genes (0.45 and 0.57% of eligible genes) in the two clones respectively ([Fig. 2c--d](#F2){ref-type="fig"}, [Supplementary Table 4 and Supplementary Fig. 11](#SD1){ref-type="supplementary-material"}). Again, X-chromosome genes were highly significant for clonal monoallelic expression ([Fig. 2d](#F2){ref-type="fig"}), verifying sensitivity.

Clonal aRME genes were expressed at significantly lower levels than other genes (*P*\<10^−9^, Wilcoxon test, [Fig. 2e](#F2){ref-type="fig"}), with a median of only \~2 RNA copies per cell (estimated using spike-in RNA). The clonal aRME expression was not dosage compensated, as clonal aRME tended to produce half the expression-level recorded in non-clonal populations (*P*-values 1.8x10^−3^ and 4.4x10^−6^, Wilcoxon test) ([Fig. 2f](#F2){ref-type="fig"}). Furthermore, comparing clonal aRME to monoallelic observations in non-clonal cells (essentially only dynamic aRME) revealed equal transcriptional output ([Fig. 2f](#F2){ref-type="fig"}). Thus, clonal aRME in primary fibroblasts mainly affects low-expressed genes without dosage compensation. Clonal aRME genes were enriched for membrane, extracellular and signaling functions ([Supplementary Table 5](#SD1){ref-type="supplementary-material"}). Five genes (*Mr1, Chn1, Ceacam1, Entpd1* and *5830432E09Rik*) had clonal aRME in both clones, either from the same or opposite alleles in the clones ([Supplementary Table 4](#SD1){ref-type="supplementary-material"}). Although this represents a statistically significant overlap (*P*\<10^−3^, hypergeometric distribution) it also highlights the scarcity of clonal aRME and that most clonal aRME genes differ between clones.

Next, we determined the prevalence of dynamic and clonal aRME in a somatic cell type *in vivo* for the first time. A male human donor was vaccinated with a yellow fever vaccine (YFV-17D), and blood samples were collected at the acute (day 15) and memory phase (day 136) of the vaccine response ([Fig. 3a](#F3){ref-type="fig"}). We tracked the CD8^+^ T-cell responses using HLA class I dextramers that identified cells responding to an immunodominant (HLA-A02:01/LLWNGPMAV, "HLA-A2") and a subdominant (HLA-B07:02:RPIDDRFGL, "HLA-B7") T-cell epitope[@R22] by fluorescence-activated cell sorting (FACS) ([Supplementary Fig. 12](#SD1){ref-type="supplementary-material"}). We sequenced the transcriptomes[@R19] of individual *in vivo* T-cells (n=545 post quality filtering), and reconstructed their rearranged T-cell receptor sequences (TCR-α and TCR-β) ([Online Methods](#S2){ref-type="sec"}). As rearrangements of the two TCR chains result in immense sequence variability[@R23], cells with identically rearrangements were identified as clones ([Supplementary Table 1b](#SD1){ref-type="supplementary-material"}). We identified 32 *in vivo* T-cell clones with 3--20 sampled cells each. To identify SNPs, we performed exome sequencing of the donor, and used confirmed SNPs to determine allelic expression in the single T-cells (mean 1,846 genes expressed; 806 allele-informative genes passing SNP filtering). We observed aRME for \~60--85% of expressed genes (RPKM \>20) across *in vivo* T-cells ([Fig. 3b](#F3){ref-type="fig"} and [Supplementary Fig. 13](#SD1){ref-type="supplementary-material"}). Interestingly, aRME was more prevalent in T-cells collected during the memory phase (*P*=2.6x10^−4^, Wilcoxon test) ([Fig. 3b](#F3){ref-type="fig"}), coinciding with decreased transcriptional activity in these cells ([Supplementary Fig. 14](#SD1){ref-type="supplementary-material"}). Next, we determined the prevalence of clonal aRME by comparing clonally consistent monoallelic expression to that expected from the background of fluctuating allelic expression using *in silico* pooling. Although the T-cells had high levels of dynamic aRME, clonal aRME was only observed for 0.9% (median) of genes (*P*=0.02, one-sided Wilcoxon test), demonstrating that clonal aRME is surprisingly scarce also in T-cells *in vivo* ([Fig. 3c](#F3){ref-type="fig"}). To obtain sufficient number of T-cells per clone for gene-level identification of clonal aRME, we FACS-sorted single HLA-A2-specific T-cells from the same donor into separate culture wells, and clonally expanded cells *ex vivo* using autologous-antigen-presenting cells and LLWNGPMAV peptide in the presence of IL-2. We collected and sequenced cells from nine clonal expansions (in total 347 T-cells, 29--48 cells per clone). As expected from the *in vivo* results, the gene-level test identified a small number of clonal aRME genes, most notably a significant (*P*=1.6x10^−8^) clonal RME of *KLRB1* (Killer Cell Lectin-Like Receptor) in one clone ([Fig. 3d](#F3){ref-type="fig"}) and allelic imbalance in other clones ([Supplementary Figs. 15--16 and Supplementary Table 6](#SD1){ref-type="supplementary-material"}). Additionally, we noted clone-consistent aRME for *CD7* (T-cell antigen) in two clones with opposite alleles expressed. Both these genes are immune related and membrane associated. We conclude that even in T-cells with high levels of monoallelic expression, the vast majority of aRME is dynamic with only sparse clonal aRME.

We detected remarkable variation in dynamic aRME across different cell types as well as among equivalently cultured fibroblasts (4--33%, [Fig. 1b--c](#F1){ref-type="fig"}). We therefore pursued determinants of dynamic aRME levels, hypothesizing that increased transcription rates in larger cells[@R24] could result in lowered levels of dynamic aRME. We therefore picked and sequenced large (ø~dissociated~ 25--35µm) and small (ø~dissociated~ 10--20µm) fibroblasts in culture, and expectedly, large cells contained more polyA^+^ RNA than small cells (*P*=5.3x10^−9^, Wilcoxon test) ([Supplementary Figs. 17-18](#SD1){ref-type="supplementary-material"}). Importantly, large cells had lower degree aRME than small cells (*P*=3.0x10^−8^, Wilcoxon test, median 9.1%, and 17% of genes respectively) ([Fig. 4a](#F4){ref-type="fig"}). This was supported by split-cell control experiments ([Online Methods](#S2){ref-type="sec"} and [Supplementary Fig. 19](#SD1){ref-type="supplementary-material"}), analytically inferring less monoallelic expression in large (median 7.8% of genes) than in small (median 15% of genes) fibroblasts from the paired allelic calls in split-cell lysates (*P*=3.3x10^−3^, Wilcoxon test) ([Fig. 4b](#F4){ref-type="fig"}). Experiments considering intermediate cell sizes, further supported a dependence between size and dynamic aRME ([Supplementary Fig. 20](#SD1){ref-type="supplementary-material"}). Correlation between cellular size (determined by FACS) and degree dynamic aRME was furthermore observed in T-cells (Pearson correlation=--0.33, *P*=2.1x10^−10^, [Fig 4c](#F4){ref-type="fig"}). Across additional mouse *in vivo* cell types we found that aRME levels varied with the total RNA content ([Supplementary Fig. 21](#SD1){ref-type="supplementary-material"}). In addition to maintaining overall RNA concentrations[@R24], we found evidence that concentrations for cellular compartments are maintained ([Supplementary Tables 7--11](#SD1){ref-type="supplementary-material"}), e.g. membrane- and cytosol-related transcripts were elevated along with increased cell size, as recently hypothesized[@R25]. Using the fibroblast data, we further investigated how the degree dynamic aRME varies with cell-cycle phase. Using the most-variable cell-cycle genes, we classified the cells into G0, G1 and S/G2/M phases ([Supplementary Fig. 22](#SD1){ref-type="supplementary-material"}; S/G2/M could not be sub-stratified). Interestingly, levels of aRME were elevated in the "resting" G0 phase (*P*≤2x10^−5^) ([Fig. 4d--e](#F4){ref-type="fig"}), in line with elevated aRME in human memory T-cells *in vivo* ([Fig. 3b](#F3){ref-type="fig"}) that also reside primarily in G0[@R26].

Here we used single-cell transcriptomics to dissect the nature of monoallelic expression in somatic cells. In contrast to previous studies that analyzed bulk-populations of longer-term expanded cell cultures[@R8],[@R10],[@R11],[@R14],[@R15], we show that clonal aRME is very scarce (\<1%) in primary and *in vivo* cells. Indeed \>95% of observed cellular aRME was dynamic, with levels correlating with the transcriptional activity of the cells and further reflected from immune-activated responses and cell-cycle phase. These data alter the interpretation of several previous reports on monoallelic expression[@R27]--[@R33], as cellular observations of monoallelic expression alone is not indicative of stable allele-level regulation. This also questions the notion of widespread clonal aRME affecting thousands of genes[@R8],[@R10],[@R13],[@R34]. The revelation that clonal aRME appear only at miniscule levels in somatic primary and *in vivo* cells advances our knowledge of allele-specific gene expression and shed light on how variable expressivity and penetrance may emerge from aRME. Thus, in addition to heterogeneity emerging from scarce clonal aRME[@R8], by far the majority of cellular variability in allelic expression occurs randomly throughout somatic cell populations and fluctuates over time.

Experimental procedures {#S2}
=======================

Derivation of primary mouse fibroblasts {#S3}
---------------------------------------

Primary fibroblasts were derived from adult CAST/EiJxC57BL/6J or C57BL/6JxCAST/EiJ mice (ethical permit: N343/12, Jordbruksverket) by skinning, mincing and culturing tail explants in fibroblast medium ([Supplementary Note 2](#SD1){ref-type="supplementary-material"}). For one clone (cl6) the fibroblasts were derived from minced E14.5 skin instead of tails, using the same procedure. After removal of explants, the culture was passaged twice to attain a pure fibroblast culture. Cells from passage 2--4 were dissociated (TrypLE Express, Gibco Ref. 12604-013), diluted to low cell density, and cells were picked by mouth pipetting using a thin glass capillary under 10x or 20x magnification. Cells for RNA-seq were transferred to RNAse-free PCR tubes containing 2µl Smart-seq2 lysis buffer and snap-frozen on dry ice.

Single-cell RNA-sequencing: Reverse transcription and cDNA amplification {#S4}
------------------------------------------------------------------------

Smart-seq2 cDNA libraries were prepared as described earlier[@R19] and outlined in [Supplementary Note 2](#SD1){ref-type="supplementary-material"}. The cDNA was purified using AMPure XP beads (Beckman Coulter, Ref. A63882) and inspected on an Agilent 2100 Bioanalyzer to determine cDNA concentration and size distribution.

Single-cell RNA-sequencing: Tagmentation and sequencing {#S5}
-------------------------------------------------------

Successful cDNA libraries were tagmented, either using the Nextera XT DNA kit (Illumina Cat. FC-131-1024) or using our in-house-generated Tn5 (which produces sequencing libraries of indistinguishable characteristics to those generated using the Nextera XT kit)[@R35]. Details on tagmentation and library amplification are available in [Supplementary Note 2](#SD1){ref-type="supplementary-material"}. Libraries were purified using AMPure XP beads and inspected on an Agilent 2100 Bioanalyser. Sequencing was performed on an Illumina HiSeq2000. All mouse single-cell RNA-seq libraries used in the analyses of aRME are listed in [Supplementary Table 1](#SD1){ref-type="supplementary-material"} and deposited to GEO (GSE75659).

Generation of libraries from split-cell lysates {#S6}
-----------------------------------------------

Split-cell libraries were prepared as for single cells, with the following modifications: Single cells were lysed in 4µl lysis buffer instead of 2µl, and the lysate was thoroughly homogenized by pipetting up and down. 2µl of the homogenized lysate was then transferred to two separate tubes, each containing 0.5µl lysis buffer (to facilitate complete release of the lysate), and processed into sequencing libraries. Only split-pairs that generated similar Agilent Bioanalyzer profiles were selected for sequencing.

Exogenous spike-in RNA {#S7}
----------------------

Spike-in RNA (ERCC, Ambion, Ref. 4456740) was diluted in 10mM Tris-HCl pH7.5. 0.1µl of diluted (1:109,658, stock:final concentration) ERCC was added to each cell's RT priming buffer (corresponding to 56,848 ERCC molecules). For T-cell libraries spike-in RNA was diluted 1:1,200,000 and 0.1µl (corresponding to 5,195 ERCC molecules) per reaction was added to the RT priming buffer.

Monoclonal fibroblasts {#S8}
----------------------

Single fibroblasts (from passage 2--4) were placed within marked areas in the bottom of gelatinized culture dishes containing fibroblast medium, observing the release of a single cell per dish under microscope. Monoclonally expanding cells were picked after 2--7 cellular divisions. For one clone (cl7), we also picked multi-cell samples of 5 or 15 cells that were jointly lysed and processed into sequencing libraries.

Human subjects for isolation of T-cells {#S9}
---------------------------------------

Human volunteers were recruited to participate in an ongoing study examining the longitudinal immune response to the yellow fever vaccine YFV 17D (approved by the Regional Ethical Review Board in Stockholm, Sweden: 2008/1881-31/4, 2013/216-32 and 2014/1890-32). A single subject (ID: YFV2001(male)) was selected for in depth analysis based on being both HLA-A2 and HLA-B7 positive and having T-cell responses against YFV epitopes presented on both HLA types. Peripheral blood was collected at day 15 and day 136 after vaccination. Peripheral blood mononuclear cells (PBMCs) were isolated by density centrifugation (Lymphoprep, Stem Cell Technologies, Ref. 07801) and stored in liquid nitrogen in 90% FCS and 10% dimethylsulfoxide (DMSO) until sorting.

Single-cell sorting of human CD8^+^ T-cells {#S10}
-------------------------------------------

Cryopreserved PBMCs were thawed and re-suspended in cold FACS buffer (PBS, 2% bovine serum, 2mM EDTA). CD8^+^ T-cells were enriched by negative selection (Miltenyi Human CD8 negative selection kit, Ref. 130-096-495), and were incubated for 15 min with either HLA-B07:02/RPIDDRFGL-dextramers (day 15 and day 136 cells) or HLA-A02:01/LLWNGPMAV-dextramers (day 15 cells) (Immudex, Denmark), followed by incubation with a panel of surface antibodies to detect live CD3^+^CD8^+^ T-cells (CD3-Alexa Flour 700 (UCHT1, BD Biosciences), CD8-APC Cy7 (SK1, BD Biosciences), CD4-PE-Cy5 (RPA-T4, Ebiosciences), CD14-Horizon V500 (MΦP9, BD Biosciences), CD19-Horizon V500 (HIB19, BD Biosciences), and Live/Dead Fixable Aqua dead cell stain kit (Invitrogen, Cat. L34957)). After 30 minutes of incubation at 4°C, the cells were washed and resuspended in cold FACS buffer for sorting. The cells were sorted using single-cell mode on a BecktonDickinson ARIA III cell sorter (equipped with a 405nm violet laser, 488nm blue laser, 561nm yellow/green laser, and 633nm red laser) into PCR plates containing 4ul Smart-seq2 lysis buffer.

*Ex vivo* expansion of human primary T-cells {#S11}
--------------------------------------------

CD8^+^ T-cells were isolated by negative selection from thawed cryopreserved PBMCs and were stained with the HLA-A2/LLWNGPMAV dextramer and antibodies as described above. Single live CD8^+^CD3^+^HLA-A2 dextramer^+^ cells were sorted directly into 96 well U-bottom plates containing 2μg/ml peptide (LLWNGPMAV), 20U/ml IL-2, and 50.000 irradiated (40Gy) CD3-depleted autologous PBMCs in complete T-cell media ([Supplementary Note 2](#SD1){ref-type="supplementary-material"}) and were cultured for 18 days. Every 4--5 days half of the media was replaced with fresh T-cell media containing 50U/ml IL-2 and 2μg/ml peptide, and the wells were visually inspected for proliferation. After 18 days, nine expanded clones were selected for single-cell sorting for RNA-seq based on the presence of sufficient cell numbers (\>100) and no evidence of contaminating cells (all live cells were CD8^+^ and bound the HLA-A2/LLWNGPMAV dextramer). Single-cell RNA-seq libraries were generated as described below for the *in vivo* studies on YFV-specific CD8^+^ T-cells.

Single-cell RNA--seq on human T-cells {#S12}
-------------------------------------

Smart-seq2 libraries from T-cells were prepared as described for mouse cells, with minor modifications ([Supplementary Note 2](#SD1){ref-type="supplementary-material"}). All T-cell single-cell RNA-seq libraries used in the analyses are listed in [Supplementary Table 1](#SD1){ref-type="supplementary-material"} and deposited to GEO (GSE75659).

Exome sequencing {#S13}
----------------

Exome capture was performed on unsorted PBMCs from donor YFV2001 using the Nextera Exome Sequencing kit (Nextera Rapid Capture Expanded Exome Kit, Illumina, Ref. FC-140-1000).

Computational procedures {#S14}
========================

Alignment of reads and allelic calling for mouse cells {#S15}
------------------------------------------------------

Reads were aligned using RNA-STAR[@R36] independently towards the mm9 genome assembly (C57 genotype) and an in-house generated CAST mm9 assembly ([Supplementary Note 2](#SD1){ref-type="supplementary-material"}). We counted C57- and CAST-informative bases for each gene, using the samtools mpileup command. To eliminate false SNP calls, occurring at low frequency, we only conceded the allelic calls for genes with ≥3 allele-informative reads. The allelic expression of each gene in each cell was called "biallelic", "reference monoallelic", "alternative monoallelic" or "not detected" ([Supplementary Fig. 6a](#SD1){ref-type="supplementary-material"}). A gene was called monoallelically expressed in a cell if one allele contributed ≥98% of the genotype-informative bases. Thus we allowed for up to 2% of reads to be aligning to the other allele without calling it "biallelic", in order to tolerate a small degree of PCR and sequencing errors known to affect high-expressed genes in particular[@R16]; considerably more stringent than previous studies RNA-seq studies[@R14],[@R15],[@R37],[@R38]. We demonstrated that our criteria (≥98% of the reads from one allele, and ≥3 allele-informative reads) were robust and resulted in accurate calls through analyses of genes on the X chromosome in male cells (i.e. cells with only one parental X chromosome) ([Supplementary Fig. 3a--b](#SD1){ref-type="supplementary-material"}). We verified that SNPs within the same genes and cells provided coherent allelic information ([Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}). Fibroblasts expressed on average 10,702 genes. The number of allele-informative autosomal genes, eligible in the gene-level test for fibroblasts, was 8,264--9,195 genes, and the number of allele-informative genes with mean RPKM \>20 in fibroblasts was 4,514.

Expression levels {#S16}
-----------------

We calculated RPKM values (reads per kilobase and million mapped reads) using rpkmforgenes[@R39] version 7 Feb 2014 with uniquely mapped reads; Ensembl annotation (from UCSC genome browser, last modification date 11 April 2012) for mouse, and hg19 for human; length compensation for unmappable positions[@R40] and the settings -fulltranscript -mRNAnorm -rmnameoverlap and -bothendsceil.

Percent monoallelically expressed genes {#S17}
---------------------------------------

Percent monoallelically expressed genes for each cell was calculated as the number of genes with monoallelic calls divided by the total number of genes with informative (biallelic or monoallelic) calls in the cell multiplied by 100, including genes with mean expressions above 1 or 20 RPKM over the group of cells considered (thresholds stated in figure legends). The 20 RPKM threshold was applied when estimating total aRME in fibroblast cells, since at this threshold the false negatives and false positives monoallelic calls are in balance both in previous experiments[@R16] and in the split-cell experiments on the mouse fibroblasts. The 1 RPKM threshold was applied when performing tests on clonal aRME, since clonal aRME genes were expressed at these low levels.

Analyses of allelic calls in split-cell experiments {#S18}
---------------------------------------------------

We inferred monoallelic expression and allelic dropouts in a cell before its lysate were split into two fractions and tubes using the analytical model we recently developed[@R16]. In brief, we compared allelic calls for each gene in the paired libraries and determined the fraction of genes for which the splitted cells gave coherent calls, and the fraction of genes with different calls ([Supplementary Note 2](#SD1){ref-type="supplementary-material"}). We introduced equations that model the observed allelic calls and account for allelic losses (e.g. from biallelic to monoallelic or not detected; from monoallelic to not-detected) as detailed in [fig. S26](#SD1){ref-type="supplementary-material"} in Deng et al.[@R16]. We solved the equations to find the fraction of monoallelic expression (x), the allelic losses (z) and the fraction biallelic expression (y). From these variables, we calculated the fraction of expressed genes that were monoallelic as x/(x+y) ([Supplementary Fig. 19a--b](#SD1){ref-type="supplementary-material"}). Since z would depend on the starting number of transcripts, we inferred x, y, z for different expression levels (i.e. RPKM bins) and we plotted the inferred variables as a function of expression level ([Supplementary Fig. 19c--d](#SD1){ref-type="supplementary-material"}). Importantly, the analytical model solves the allelic dropouts and monoallelic expression per expression bin, and it is a threshold-independent method that can account for varying dropout levels depending on RNA contents of cells prior to lysis and splits. Therefore the approach allows for varying allelic dropouts in the analyses of each split-cell pair, and we observed that smaller fibroblasts obtained slightly higher dropout levels than larger fibroblasts ([Supplementary Fig. 19c--d](#SD1){ref-type="supplementary-material"}).

Corrections for chromosomal aneuploidies {#S19}
----------------------------------------

We surveyed the allelic calls along chromosomes to detect large-scale chromosomal aberrations, including aneuploidies. These were identified as chromosomes, or parts of chromosomes, where a large number of genes were deviating in allelic expression in favor of CAST or C57 genotypes. Chromosomes were flagged if abs(monoallelic calls CAST -- monoallelic calls C57) \> 50% and were then visually inspected. [Supplementary Note 2](#SD1){ref-type="supplementary-material"} provides details on flagged cells and chromosomes.

Inferring number of RNA molecules per cell from spike-ins {#S20}
---------------------------------------------------------

To determine the total number of polyA^+^ molecules per cell (used for [Supplementary Fig. 21](#SD1){ref-type="supplementary-material"}), we divided the number of added ERCC spike-in molecules by the total RPKM for spike-ins in each a sample and multiplied by the total RPKM for genes ([Supplementary Note 2](#SD1){ref-type="supplementary-material"}).

Identification of genes with imprinted or strain-biased allelic expression {#S21}
--------------------------------------------------------------------------

We translated the CAST and C57 calls to maternal and paternal calls, according to the parental genotypes. *P*-values for imprinted allelic expression were calculated using Fisher's exact test on the frequency of monoallelic expression in a parental-specific manner compared to the overall call frequencies ([Supplementary Fig. 6c](#SD1){ref-type="supplementary-material"}). To consider a gene imprinted, and for inclusion in [Supplementary Table 3a](#SD1){ref-type="supplementary-material"}, the criteria were coherent monoallelic parental-specific calls in ≥90% of the cells and *P*\<0.05 for the paternal bias in monoallelic expressions. We further performed imprinting analyses using bulk RNA sequencing on fibroblasts (described in [Supplementary Note 2](#SD1){ref-type="supplementary-material"}). We identified genes with strain-biased allelic expression using the observed frequencies C57 or CAST monoallelic in cells ([Supplementary Fig. 6b](#SD1){ref-type="supplementary-material"}), and we evaluated the frequency deviation from *P*=0.5 using a binominal test ([Supplementary Fig. 6d](#SD1){ref-type="supplementary-material"}). Previously known imprinted (genes in the *GeneImprint* repository) and novel imprinted genes were filtered out before strain analyses.

Analysis of clonal random monoallelic expression {#S22}
------------------------------------------------

Clone-consistent random monoallelic expression was investigated using two approaches. To estimate the percentage of genes with clonal aRME in mouse primary fibroblasts or human *in vivo* T-cells we compared the observed frequency of clone-consistent monoallelic calls over the cells of each clone separately to the expected clone-consistent aRME deriving from dynamic aRME through "*in silico* pooling" of cellular allelic calls ([Supplementary Fig. 6e](#SD1){ref-type="supplementary-material"}). Observed clone-consistent monoallelic expression was computed as the percentage of detected genes with allele-consistent monoallelic in the clonal cells. The expected background frequency of clone-consistent monoallelic expression (being consistent monoallelic over cells by random chance alone, due to transcriptional bursting and/or technical dropout of RNA species) was computed through *in silico* pooling of non-clonal cells and/or allelic calls. We evaluated the background frequencies derived from *in silico* pooling of either random cells or randomized allelic calls and both approaches yielded similar background estimates. For analyses presented in the study, we used randomized allelic calls rather than cells, since pooling of randomized calls conserve possible clone-specific patterns of expressed genes. In each round (500 random samplings), we replaced informative allelic calls per gene (i.e. calls assigned as biallelic, reference-monoallelic, or alternative-monoallelic) in the cells of each clone, with a random informative call with probability according to the frequency at which the different calls occurred in the non-clonal cell population ([Supplementary Fig. 6b](#SD1){ref-type="supplementary-material"}). The clonal aRME (reported in [Supplementary Fig. 6e](#SD1){ref-type="supplementary-material"}, [Fig. 1e](#F1){ref-type="fig"} and [Fig. 3c](#F3){ref-type="fig"}) was defined as the observed percent of genes with clone-consistent monoallelic expression minus the median percent genes with clone-consistent monoallelic expression in 500 random samplings.

Gene-level test to identify genes with clonal aRME {#S23}
--------------------------------------------------

To identify individual genes with clonal aRME in fibroblasts and *ex vivo* T-cells we applied a gene-level test ([Supplementary Fig. 6f](#SD1){ref-type="supplementary-material"}), assessing the statistical significance of skew in allelic call frequencies in a clone compared to the overall call frequencies in non-clonal cells (i.e. taking genetic effects into account). We classified genes as subjected to clonal aRME based on: *i)* Fisher's exact test *P*\<0.05 (one-sided test for either over-representation of reference-monoallelic calls or over-representation of alternative-monoallelic calls) and *ii)* required consistent monoallelic calls in ≥90% of the cells with informative calls for the particular gene and clone. The rationale for requiring 90% of cells having clone-consistent calls was based on analyses of imprinted genes (see the shape of the distribution in [Fig. 2b](#F2){ref-type="fig"}). Imprinted genes were filtered out before all clonal aRME analyses. To account for multiple testing, we computed the expected number of false positives (E-values) using randomly sampled non-clonal cells (1000 randomizations per clone).

Identification of T-cell *in vivo* clones {#S24}
-----------------------------------------

T-cell clones were identified based on cDNA sequences corresponding to the TCR-alpha (TCRα) and TCR-beta (TCRβ) chains using the MiTCR platform[@R41], and a list of putative TCRα and TCRβ sequences was identified for each single-cell RNA-seq library. Reads were filtered to remove unproductive sequences corresponding to erroneous calls or PCR artifacts (as annotated in the MiTCR output). A secondary pipeline was developed in which publicly available sequences in the NCBI and Ensemble gene repositories of TCRα- and TCRβ-related gene components were used as reference to screen for reads aligning to these regions. Reads were aligned to this reference, assembled using Velvet[@R42], and submitted to the International ImMunoGeneTics (IMGT) TCR sequence identifying platform[@R43]. The resulting hits were compared with the MiTCR screen to validate the individual sequences. In most cases either one or both of the TCR chains could be identified with both methods, and only cells with a high degree of certainty, presenting both the TCRα and TCRβ sequences, were considered for analysis of their clonal identity. Since both TCR chains are generated as separate recombination events it is extremely rare that two distinct T-cells will arise bearing identical both TCRα and TCRβ chains at the nucleotide level[@R23]. Cells with identical TCRα and TCRβ sequences were consequently classified as clones. Clones with at least three cells were considered for further analysis of clonal aRME, resulting in 32 individual *in vivo* T-cell clones.

Identification of heterozygous SNPs in human donor T-cells {#S25}
----------------------------------------------------------

To identify high-confidence SNPs in the male donor, we considered only heterozygous bases supported in the exome data and present in dbSNP (build 138) reference database. The criteria for inclusion were: ≥3 reads of each SNP variant in the exome data and ≤50-fold difference between the two, and that both SNP bases were validated by the single-cell RNA-seq data (informative call for the SNP in ≥1% of the cells). To filter out SNPs expressed with strong genetic bias, imprinted genes, and possible remaining false-positive SNPs, we discarded SNPs with a detected bias for one base (reference or alternative) \>70% over all cells ([Supplementary Fig. 3c](#SD1){ref-type="supplementary-material"}), and all X-chromosome genes. This resulted in the inclusion of 1,010 confirmed autosomal SNPs expressed in the human donor's T-cells, corresponding to 806 unique genes post filtering. For genes with multiple SNPs we used the most informative SNP (i.e. the SNP with highest number of reads). T-cells expressed (RPKM\>1) on average 1,846 genes, and the number of expressed genes varied between the acute and memory phase ([Supplementary Fig. 14a](#SD1){ref-type="supplementary-material"}). The number of eligible allele-informative genes in *ex vivo*-expanded T-cell clones ranged between 370 and 660 ([Supplementary Fig. 15](#SD1){ref-type="supplementary-material"}), and the number of allele-informative genes with mean RPKM \>20 was 399.

Allelic calling for human cells {#S26}
-------------------------------

For the analysis of allelic expression in T-cells, we used the same criteria and analyses as for fibroblasts (but using human reference/alternative SNPs rather than mouse CAST/C57 SNPs), considering genes with a mean expression of at least 1 or 20 RPKM over the group of T-cells considered, as stated in the figure legends.

GO analyses of genes correlating with cellular size and mRNA content {#S27}
--------------------------------------------------------------------

GO analyses (described in detail in [Supplementary Note 2](#SD1){ref-type="supplementary-material"}, results in [Supplementary Table 7-11](#SD1){ref-type="supplementary-material"}) were performed using DAVID[@R44],[@R45], and genes expressed in fibroblasts (genes with mean expression \>1 RPKM) were used as background set.

Cell-cycle classification on fibroblast cells {#S28}
---------------------------------------------

The cell-cycle phase of individual fibroblasts cells was identified by regressing the cell-cycle genes identified by Whitfield[@R46]. A fit was performed using the R function glmgam.fit(), as previously described by Brennecke et al.[@R47]. The 100 cell-cycle genes presenting the greatest variability were used for principal component analysis whereby three phases of the cell cycle could be separated.
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![The vast majority of aRME in primary mouse fibroblasts is dynamic.\
(**a**) Schematic overview of the experimental design. (**b**) Histogram showing percent aRME in randomly picked primary mouse fibroblasts (n=163). (**c**) Percent autosomal genes with bi- or monoallelic expression in single cells, after aggregating all cells of a clone, and expected levels from randomly pooling allelic calls of the same number of non-clonal cells. Dots represent percent monoallelic genes observed in single cells and bars depict the average. Observed allelic expression on the X-chromosome is shown to the right of each clonal set. Biallelic genes on female X-chromosomes are X-inactivation escapees ([Supplementary Fig. 7--9](#SD1){ref-type="supplementary-material"}). Sex and number of sequenced cells (out of all cells of the clone) are indicated above. (**d**) Percent of genes with aRME when sequencing transcriptomes of 5 or 15 pooled clonal cells (dots), and values obtained after *in silico* pooling of clonal or non-clonal cells shown as boxplots; indicating median (belt), interquartile range (box) and farthest points at maximum 1.5 times the interquartile rage (whiskers). Expression threshold in (b**--**d): RPKM\>20. (**e**) Percent clonal aRME in the seven clones (circles) (observed minus expected), for genes detected either above 20 or 1 RPKM. The *P*-value denotes a median significantly greater than zero (one-sided Wilcoxon test). "ns": not significant.](emss-69807-f001){#F1}

![Scarce clonal aRME in low-expressed genes\
(**a**) Genes with parental-specific (imprinted) monoallelic expression, ordered and colored according to chromosomal localization, with **--**log~10~ *P*-values (Fisher's exact test) on y-axis. (**b**) Gene scatter with fraction cells having consistent maternal or paternal monoallelic expression (x-axis) plotted against the **--**log~10~ *P*-values (Fisher's exact test). Genes with *P*\<0.05 and consistent monoallelic in ≥90% of expressing cells were classified parent-of-origin-specific monoallelic, all being known imprinted genes except the novel candidates in brackets (*DLX5* is known imprinted in human). (**c**) Test on clonal aRME (as in (a)) for male primary fibroblast clone 6 (n=38 cells), and scatterplot (as in (b)). E-values denote expected number of false positives above thresholds. (**d**) Test on clonal aRME for female primary fibroblast clone 7 (n=60 cells) and scatterplot (as in (c)). (**e**) Expression-level boxplots of clonal aRME (colored) and other genes (gray) in clones 6 and 7. *P*-values from two-sided Wilcoxon test. (**f**) Boxplots of relative expression of clonal aRME genes, over whole cell populations (left), or single cells expressing monoallelic (clonal or dynamic aRME) in both clone and non-clonal cells. *P*-values signify deviation from equal expression (two-sided Wilcoxon test). Additional boxplots (right) show relative expression levels in cells with dynamic aRME and biallelic expression, demonstrating the expected \~1:2 expression-level when transcribing 1 versus 2 alleles. (a**--**f) Threshold: RPKM\>1.](emss-69807-f002){#F2}

![Dynamic and clonal aRME in human T-cells.\
(**a**) Schematic representation of the experimental design. (**b**) Boxplots of percent aRME genes in HLA-B7 restricted T-cells, isolated at day 15 (red) or 136 (blue) after vaccination; and in all *in vivo-* (green) and *ex vivo-expanded* (orange) T-cells. Threshold: RPKM\>20. (**c**) Upper panel: Percent aRME in 32 *in vivo* T-cell clones (circle: per cell, dot: median) and in all *in vivo* T-cells as a boxplot to the right. Lower panel: Percent clone-consistent aRME (observed minus expected, from sampled *in silico* pooling) as blue boxplots. The pink boxplot (lower right) and red solid line show median percent clonal aRME estimated over all clones. *P*-value for clonal aRME above zero according to a one-sided Wilcoxon test. Threshold: RPKM\>1. (**d**) Example of gene-level identification on an *ex vivo*-expanded T-cell clone (clone C), showing highly significant clonal aRME of *KLRB1* (Scatter plots as described in [Fig. 2c--d](#F2){ref-type="fig"}).](emss-69807-f003){#F3}

![Cellular size and cell-cycle phase affect the degree dynamic aRME.\
(**a**) Observed allelic expression in primary fibroblasts of large and small cellular size. *P*-value: two-sided Wilcoxon test. (**b**) Percent monoallelic expression in large and small fibroblasts inferred by split-cell analysis. *P*-value: two-sided Wilcoxon test. (**c**) Scatter plot and Pearson correlation of percent aRME and cell size (estimated by FACS) in *ex vivo*-expanded T-cells. (**d**) Principal component analysis (scatterplot of component 1 and 2) of fibroblasts using the top 100 most-variable cell-cycle genes, with cells colored according to cell-cycle classification. (**e**) Boxplots of percent aRME in fibroblasts of different cell-cycle phases. *P*-values: two-sided Wilcoxon test. (a**--**d) Expression threshold: RPKM\>20.](emss-69807-f004){#F4}
